A Philadelphia company developing immunotherapies to treat cancer raised $5 million in a private stock sale, according to documents filed with the Securities and Exchange Commission.
Immunome is seeking to raise a total of $12 million in its current round of equity financing, according to the filing.
Jane Hollingsworth, CEO of Immunome, declined through a spokeswoman to comment on the financing saying she preferred to wait until the stock sale was completed before discussing the use of the proceeds.
Immunome was founded at the Lankenau Institute for Medical Research in Wynnewood. It is one of a handful of Philadelphia biopharmaceutical companies focused on immuno-oncology, a rapidly expanding field in cancer treatment in which the body’s own immune system is enhanced through bioengineering to identify and destroy tumor cells.
Breaking news and the stories that matter to your neighborhood.
To read the full article, click here.
For more business news, visit Philadelphia Business Journal.